Bottom line
SPBO vs XLV: the short answer
SPBO (State Street(R) SPDR Portfolio Corporate Bond ETF) and XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) are both etfs.
But SPBO is far broader, holding 4,052 positions to 65 for XLV, so beyond the top names it adds exposure XLV doesn't have.
SPBO is cheaper at 0.03% vs 0.08% — a difference of $5.00 a year per $10,000 invested.
Over five years, XLV returned +8.1% a year vs +0.1% for SPBO.
Updated Nov 19, 2026
SPBO vs XLV side by side
| SPBO | XLV | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | SPDR (State Street) | SPDR (State Street) |
| Category | Corporate Bond | Health Care Sector |
| Expense ratio | 0.03% | 0.08% |
| Annual cost per $10k | $3 | $8 |
| 10-yr cost on $10k (prospectus) | $39 | $103 |
| Max front load | None | None |
| 12b-1 fee | 0% | 0.02% |
| 1-yr return | +7.9% | +14.5% |
| 5-yr return (annualized) | +0.1% | +8.1% |
| 10-yr return (annualized) | +3.3% | +9.8% |
| Best quarter | +9.4% | +14.5% |
| Worst quarter | −7.5% | −12.7% |
| Net assets (fund) | $2.0B | $40.6B |
| Number of holdings | 4,052 | 65 |
| Portfolio turnover | 25% | 2% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | SPBO | XLV | Difference |
|---|---|---|---|
| 2025 | +7.9% | +14.5% | −6.6% |
| 2024 | +2.5% | +2.5% | +0.0% |
| 2023 | +9.0% | +2.0% | +7.0% |
| 2022 | −15.9% | −2.1% | −13.8% |
| 2021 | −1.1% | +25.9% | −27.0% |
| 2020 | +10.4% | +13.3% | −2.9% |
| 2019 | +14.8% | +20.7% | −5.9% |
| 2018 | −2.3% | +6.3% | −8.6% |
| 2017 | +5.8% | +21.7% | −15.9% |
| 2016 | +5.4% | −2.8% | +8.2% |
Source: Fund prospectus bar charts
Holdings overlap
SPBO and XLV share none of their top holdings.
SPBO top 10
- State Street Global Advisors — 2.74%
- Bank Of America Corp — 0.27%
- Bank Of America Corp — 0.22%
- Anheuser-busch Co/inbev — 0.20%
- State Street Global Advisors — 0.19%
- Bat Capital Corp — 0.18%
- Bank Of America Corp — 0.16%
- Bank Of America Corp — 0.16%
- Cvs Health Corp — 0.16%
- Jpmorgan Chase & Co — 0.15%
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
FAQ
What is the difference between SPBO and XLV?
Which is cheaper, SPBO or XLV?
Should I own both SPBO and XLV?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.